Oncolys BioPharma

Basic Information

Stock Code
4588
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
March 2004
Listing Year
December 2013
Official Website
https://www.oncolys.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GN I Group, Heartseed, Nexel Pharm, CANBAS, Peptidream, SanBio, Helios, Perseus, Rena Science, Tsubota Lab, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

Oncolys BioPharma is a drug discovery venture established in 2004 specializing in virus therapies for cancer and infectious diseases, and is a leading Japanese company advancing pharmaceutical development based on oncolytic virus technology.

Current Situation

Oncolys BioPharma recorded net sales of approximately 168 million yen in the fiscal year ended December 2019, with total assets of about 4.3 billion yen and capital of 7 billion yen, maintaining a solid financial foundation. Its flagship oncolytic virus therapy 'Telomelysin' (OBP-301) is advancing Phase II clinical trials in collaboration with Chugai Pharmaceutical, gaining high evaluation both domestically and internationally. It adopts a fabless business model outsourcing manufacturing and testing to reduce costs and timelines. Additionally, the fluorescent diagnostic agent 'Telomescane' has been launched to the market, contributing to sales. Various treatment candidates are under research and development, with active partnerships and investments with universities and overseas companies. It has received Sakigake Designation from the Ministry of Health, Labour and Welfare for expedited product approval, and has set a long-term vision toward 2030 for 'curing cancer without surgery.' Moving forward, it aims to differentiate in treatment areas and achieve growth through the fusion of innovative gene technology and virus therapy.

Trivia

Interesting Facts

  • Biotech venture founded on technology from Okayama University.
  • Company name derives from 'onco-' meaning cancer and 'lysis' meaning dissolution.
  • Flagship products aim to cure cancer without surgery using virus therapy.
  • Rare pharmaceutical venture with no manufacturing facilities due to fabless operations.
  • Collaborating with Taiwan's Medigen on manufacturing and development.
  • One of the first companies certified under the Ministry of Health, Labour and Welfare's Sakigake Designation system.
  • Multiple license agreements in the US, Taiwan, China, and Korea.
  • Telomescane diagnostic agent is a proprietary product based on patented technology.
  • Representative Yasuo Uratani is the founder with prior experience at Ono Pharmaceutical.
  • Subsidiary Oncolys USA Inc. handles clinical trials in the US.
  • Collaborates with immune checkpoint inhibitors as combination therapy for cancer treatments.
  • Possesses a diverse pipeline of therapeutics at various clinical stages.
  • Diversified drug development including histone deacetylase inhibitors.
  • Awarded Minister of Education, Culture, Sports, Science and Technology Prize at Japan BioVenture Awards.
  • Okayama University professor serves as co-founder and special advisor.

Hidden Connections

  • Major pharmaceuticals such as Chugai Pharmaceutical and Astellas Pharma are key shareholders and partners.
  • Partnered with Taiwan's Medigen on oncolytic virus therapy.
  • Entered joint clinical trial agreement with Cornell University in the US.
  • Links with rapidly growing CRO, CSO, and SMO businesses via diagnostic agent technology.
  • Established subsidiary in Delaware for business under US regulations.
  • Holds exclusive implementation rights to patented technology with US Geron Corporation.
  • Oncolys' representative has experience at major medical firms for multifaceted management.
  • Oncolys' virus technology is linked with gene editing technology.

Future Outlook

Growth Drivers

  • Expectations for clinical success of new virus therapies targeting solid tumors
  • Improved therapeutic efficacy through combination with immunotherapy
  • Market expansion via expanded partnerships with domestic and international pharmaceutical companies
  • Shortened development timelines through efficient non-clinical and clinical trials
  • Dissemination of innovative technology for the vision of 'curing cancer without surgery'

Strategic Goals

  • Expand market share of oncolytic virus therapy domestically and internationally
  • Enrich pipeline of therapeutics adaptable to diverse cancer types
  • Aggressively introduce gene editing technology for revolutionary treatment development
  • Build sustainable R&D structure reducing environmental impact
  • Provide products realizing improved patient QOL in cancer treatment

Business Segments

Pharmaceutical Development and Manufacturing License Provision

Overview
Monetizes in-house developed pharmaceutical technologies by licensing to pharmaceutical companies, etc.
Competitiveness
Efficient technology transfer through rigorous virus technology and fabless operations.
Customers
  • Major Pharmaceutical Companies
  • Biotech Ventures
  • Research Institutions
  • Overseas Pharmaceutical Companies
  • Medical Institutions
Products
  • Oncolytic Virus Therapy License
  • Therapeutic Development Data
  • Diagnostic Agent Manufacturing Technology
  • Non-Clinical and Clinical Trial Support
  • Fundraising Support

Clinical Testing Outsourcing Services

Overview
Provides clinical testing for diagnostic agents in development as a CRO.
Competitiveness
High-sensitivity testing leveraging patented technology for superior reliability.
Customers
  • Pharmaceutical Company Clinical Trial Departments
  • Medical Institutions
  • Research Institutions
  • CRO Companies
Products
  • CTC Testing Services
  • Diagnostic Agent Supply
  • Test Data Analysis Support
  • Clinical Trial Testing Management

Joint Research and Capital Alliances

Overview
New technology development and business expansion through alliances with various parties.
Competitiveness
Foundation technology from Okayama University and extensive industry partnerships.
Customers
  • Universities and Research Institutions
  • Domestic and International Biotech Companies
  • Venture Investors
Products
  • New Virus Therapy Development
  • Gene Editing Technology
  • New Diagnostic Agent Development

Overseas Market Expansion Support

Overview
License-outs and business expansion support targeting Asian countries.
Competitiveness
Rapid market entry achieved through cooperation with local partners.
Customers
  • Taiwanese Companies
  • Major Chinese Pharmaceuticals
  • Korean Companies
Products
  • License Grants
  • Local Clinical Trial Collaboration
  • Sales Support

Competitive Advantage

Strengths

  • Proprietary oncolytic virus technology originating from Okayama University
  • Efficient development structure via fabless operations
  • Potential for early product approval through Sakigake Designation
  • Strategic license agreements with multiple countries
  • Highly specialized researcher team despite small size
  • Strong capital base and major pharmaceutical shareholders
  • Multi-layered therapeutic pipeline
  • Proprietary patented diagnostic agent technology
  • Subsidiary establishment for global expansion
  • Active promotion of physician-led clinical trials
  • Exploration of latest gene editing technology applications
  • Abundant industry-academia-government collaboration track record
  • Cost reduction through clinical trial outsourcing
  • Research and development for wide range of cancer types
  • Early revenue generation from marketed diagnostic agents

Competitive Advantages

  • Tumor-specific virus therapy technology is a unique domain unmatched by competitors
  • Fabless model significantly reduces development risks and costs
  • Expected expedited approval via Ministry of Health, Labour and Welfare Sakigake Designation
  • Strong partnerships with Chugai Pharmaceutical, Taiwan Medigen, etc.
  • Progress in building integrated platform from drug discovery to diagnostics
  • Focus on combination therapies with diverse treatments to meet market needs
  • Adenovirus-based technology suggests high safety and efficacy medically
  • Broad patents in both pharmaceuticals and diagnostics make imitation difficult
  • Agile management and technology development despite small team
  • Proprietary fluorescent testing technology holds market superiority in early cancer diagnosis
  • Accelerating international clinical trials and growth via overseas bases
  • High technology evaluation secures multifaceted public subsidies and grants
  • Multiple growth engines from diversified treatment development
  • Innovative concept of 'curing cancer without surgery' is readily accepted by market
  • Reliability and fundraising strength backed by major pharmaceutical shareholders

Threats

  • Risk of business stagnation from clinical trial failures
  • Risk of approval delays from regulatory changes
  • Accelerated development of similar virus therapies by competitors
  • Intensifying price competition in pharmaceutical market
  • Quality control risks at manufacturing contractors
  • Patent infringement lawsuits or intellectual property issues
  • Heightened requirements for safety proof of new virus technologies
  • Uncertainty in political and economic conditions for overseas expansion
  • Development funding shortages from deteriorating fundraising environment
  • Risk of obsolescence from rapid technological innovation
  • Deterioration of research environment from pandemics or sudden events
  • Challenges in technology succession from talent outflow

Innovations

2020: Telomelysin Phase II Trial Initiation

Overview
Initiated Phase II clinical trial targeting esophageal cancer patients in collaboration with Chugai Pharmaceutical.
Impact
Significant advancement toward product approval upon trial success.

2021: Next-Generation Telomelysin OBP-702 Non-Clinical Trial Progress

Overview
Advancing non-clinical trials for p53-introduced drug enhancing cancer cell apoptosis induction.
Impact
Heightened expectations for improved therapeutic efficacy.

2022: Telomescane F35 Improvement and New Application Research

Overview
Expanding sales of enhanced infectivity diagnostic agent and advancing diagnostic-therapeutic combination research.
Impact
Market share expansion and new application development.

2023: Cancer Immunotherapy Combination Trial Initiation

Overview
Initiated combination trials with immune checkpoint inhibitors such as pembrolizumab.
Impact
Potential expansion of treatment options and improved efficacy.

2024: Acceleration of Overseas License Agreements

Overview
Strengthening overseas expansion by concluding multiple license agreements with major companies in China, Taiwan, and Korea.
Impact
Increase in international sales and strengthened business foundation.

2025: Gene Editing Technology Introduction Research

Overview
Advancing next-generation therapeutics targeting cancer cell property neutralization using new technologies.
Impact
Foundation for creating revolutionary treatments.

Sustainability

  • Environmental load reduction and resource efficiency maximization via fabless model
  • Thorough in-house safety management to reduce biohazard risks
  • Waste reduction through improved R&D efficiency
  • Sustainable organizational revitalization via diverse talent utilization
  • Strengthened collaboration with regional medical support activities